DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia

Pharmacogenomics Journal

Volumn 13, Issue 1, 2013, Pages 27-34

  Tanaka, S ^a   Syu, A ^a   Ishiguro, H ^a,b   Inada, T ^c   Horiuchi, Y ^a,b   Ishikawa, M ^a   Koga, M ^a,b   Noguchi, E ^a   Ozaki, N ^d   Someya, T ^e   Kakita, A ^f   Takahashi, H ^f   Nawa, H ^f   Arinami, T ^a,b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c SEIWA HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^f NIIGATA UNIVERSITY   (Japan)

Author keywords

dopamine; DPP6; Kv4; schizophrenia antipsychotics; tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; DIPEPTIDYL PEPTIDASE LIKE PROTEIN 6; HALOPERIDOL; NEUROLEPTIC AGENT; REGULATOR PROTEIN; SHAL POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DPP6 GENE; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; GENE LOCATION; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHARMACOGENETICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; REGULATORY MECHANISM; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ALLELES; ANIMALS; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; INTRONS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS; SCHIZOPHRENIA;

EID: 84872931842     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.36     Document Type: Article

References (34)

1. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996; 94: 118-124.
2. Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry 2007; 191: 238-245.
3. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006; 163: 1438-1440.
4. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 2007; 257: 169-172.
5. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007; 20: 131-137.
6. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-156.
7. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T et al. Pathwaybased association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008; 18: 317-323.
8. Menza MA, Grossman N, Van Horn M, Cody R, Forman N. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991; 30: 109-115.
9. Muller DJ, Shinkai T, De Luca V, Kennedy JL. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004; 4: 77-87.
10. Malhotra AK, Murphy Jr GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-796.
11. Klawans HL, Goetz CG, Perlik S. Tardive dyskinesia: review and update. Am J Psychiatry 1980; 137: 900-908.
12. Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatr Scand 1988; 77: 369-378.
13. Saito T, Ishizawa H, Tsuchiya F, Ozawa H, Takahata N. Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism. Jpn J Psychiatry Neurol 1986; 40: 189-194.
14. Haleem DJ. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia. J Coll Physicians Surg Pak 2006; 16: 556-562.
15. Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2002: CD000207.
16. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707-747.
17. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, Miller del D et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279-282.
18. Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 2010; 25: 2809-2817.
19. Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010; 35: 1155-1164.
20. Association AP. Diagnostic and Statistical Manual of Mental Disorders, 4th revision. American Psychiatric Association: Washington, DC 1994.
21. Itoh H, Yagi G, Ogita K, Ohtsuka N, Sakurai S, Tashiro I et al. Study on the efficacy and safety of treatment with anti-psychotic drugs: an international comparative examination. Annu Rep Pharmacopsychiatry Res Found 1977; 9: 218-225.
22. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487.
23. Ishiguro H, Koga M, Horiuchi Y, Noguchi E, Morikawa M, Suzuki Y et al. Supportive evidence for reduced expression of GNB1L in schizophrenia. Schizophr Bull 2008; 36: 756-765.
24. Koga M, Ishiguro H, Yazaki S, Horiuchi Y, Arai M, Niizato K et al. Involvement of SMARCA2/BRM in the SWI/SNF chromatinremodeling complex in schizophrenia. Hum Mol Genet 2009; 18: 2483-2494.
25. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008; 82: 477-488.
26. van Es MA, van Vught PW, Blauw HM, Franke L, Saris CG, Van den Bosch L et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet 2008; 40: 29-31.
27. Tsai HT, Caroff SN, Miller del D, McEvoy J, Lieberman JA, North KE et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 336-340.
28. Zagha E, Ozaita A, Chang SY, Nadal MS, Lin U, Saganich MJ et al. DPP10 modulates Kv4-mediated A-type potassium channels. J Biol Chem 2005; 280: 18853-18861.
29. Clark BD, Kwon E, Maffie J, Jeong HY, Nadal M, Strop P et al. DPP6 localization in brain supports function as a Kv4 channel associated protein. Front Mol Neurosci 2008; 1: 8.
30. Kim J, Nadal MS, Clemens AM, Baron M, Jung SC, Misumi Y et al. Kv4 accessory protein DPPX (DPP6) is a critical regulator of membrane excitability in hippocampal CA1 pyramidal neurons. J Neurophysiol 2008; 100: 1835-1847.
31. Nadal MS, Ozaita A, Amarillo Y, Vega-Saenz de Miera E, Ma Y, Mo W et al. The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels. Neuron 2003; 37: 449-461.
32. Maffie J, Rudy B. Weighing the evidence for a ternary protein complex mediating A-type K+ currents in neurons. J Physiol 2008; 586(Part 23): 5609-5623.
33. Zhang H, Rodgers EW, Krenz WD, Clark MC, Baro DJ. Cell specific dopamine modulation of the transient potassium current in the pyloric network by the canonical D1 receptor signal transduction cascade. J Neurophysiol 2010; 104: 873-884.
34. Hahn J, Tse TE, Levitan ES. Long-term K+ channel-mediated dampening of dopamine neuron excitability by the antipsychotic drug haloperidol. J Neurosci 2003; 23: 10859-10866.